Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Attention Deficit Disorder With HyperactivityEpilepsy
Interventions
DRUG

Extended Release Methylphenidate (OROS-Methylphenidate)

"Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH."

Trial Locations (1)

02115

Childrens Hospital Boston, Boston

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Boston Children's Hospital

OTHER

NCT00323947 - Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy | Biotech Hunter | Biotech Hunter